Filed Under: Biologics, Dermatology, Immunology, Infectious Disease, Metabolic disease/endicrinology, Oncology Tagged With: AbbVie, biologic drugs, biosimilar competition, drug sales H1 2025, Eli Lilly, GLP-1 drugs, IL-23 inhibitors, immunology drugs, Keytruda patent expiry, loss of exclusivity, Merck, Novo Nordisk, obesity drugs, Oncology Therapeutics, patent cliff 2028, PD-1 inhibitors, pharmaceutical blockbusters, prescription drug market, Skyrizi, therapeutic categories Brian Buntz As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology
The influence of glucose concentration and hypoxia on VEGF secretion by cultured retinal cells
Balancing sensitivity, selectivity, and robustness across the full peptide lifecycle remains a key challenge
Read More April 10, 2025 10 Omega-3 Benefits for Men: Improve Heart, and Brain Health Fish oil is high in omega-3 fatty acids, like EPA and DHA
Semaglutide B12 injections offer an effective weight loss prescription combination for individuals seeking to achieve their weight loss goals
Whereas, the higher doses that are really good for weight reduction
